Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
This study will be looking at what dose of tremelimumab and olaparib is safe and effective in patients with persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma).
調査の概要
詳細な説明
This clinical trial was initially intended to be a Phase 1/2 trial, but the trial never moved forward to Phase 2 prior to termination.
研究の種類
介入
入学 (実際)
24
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21231
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
18年歳以上 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Signed informed consent form
- Age ≥ 18 years
- Recurrent or persistent EOC (epithelial ovarian, fallopian tube or primary peritoneal carcinoma)
- Have archival tissue or willingness to undergo a tumor biopsy
- Have measurable disease
- Have had one prior taxane-platinum-based chemotherapeutic regimen
- Have had a treatment-free interval following platinum-based therapy of less than 12 months, have progressed during platinum-based therapy, or had persistent disease after a platinum-based regimen
- Have received hormonal therapy
- ECOG Performance Status of 0 to 1
- Ability to take oral medications
- HIV, HTLV-1, HBV, and HCV negative
- Adequate organ and bone marrow function as defined by study-specified laboratory tests
- Normal blood coagulation parameters
- Life expectancy greater than 16 weeks
- Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
- Willing and able to comply with study procedures
Exclusion Criteria:
- Prior therapy with an anti-CTLA-4 antibody or PARP inhibitor
- Active infection requiring antibiotics
- Active autoimmune disease
- Active and uncontrolled intercurrent illness
- History of other cancers within the past 5 years
- Systemically active steroid use
- Receiving systemic chemotherapy or radiotherapy within 4 weeks prior to the first dose of study drug
- Use of ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir
- Requirement for chronic parenteral hydration/nutrition
- Vaccination with live attenuated vaccine within 1 month prior to first dose of study drug
- Patients with untreated brain metastases, treated brain metastases that are not stable, leptomeningeal disease, or seizures uncontrolled with standard medical therapy
- Patients with myelodysplastic syndrome/acute myeloid leukaemia
- History of diverticulitis
- History of bleeding disorder or diathesis.
- Serious or nonhealing wound, ulcer, bone fracture, or osteonecrosis of the jaw
- Major surgical procedure within 28 days of study enrollment, or anticipated while on study.
- Pregnant or breast feeding woman
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Arm A: Tremelimumab Alone
25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
|
|
|
実験的：Arm B1: DESE Tremelimumab and Olaparib
18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
|
他の名前：
|
|
実験的：Arm B2: Tremelimumab and Olaparib
25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression.
Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
|
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse events as a measure of the safety and tolerability profile of tremelimumab in combination with olaparib
時間枠：4 years
|
Number of participants experiencing study drug-related dose limiting toxicities (DLTs).
Dose escalation (phase I) portion of the trial only.
|
4 years
|
|
Fold change from baseline in the ratio of peripheral CD4+ICOShi T cells and Regulatory T cells
時間枠：4 years
|
Dose escalation (phase I) portion of the trial only.
|
4 years
|
|
Maximum Tolerated Dose (MTD) of tremelimumab combined with olaparib
時間枠：4 years
|
Dose escalation (phase I) portion of the trial only.
|
4 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
全生存期間 (OS)
時間枠：4年
|
OSは、最初の投与日から死亡またはフォローアップの終わりまで測定されます（OSは、分析時に死亡が記録されていない被験者については、被験者が最後に生存していることが判明した日付で打ち切られます）。
カプラン・マイヤー曲線に基づく推定。
|
4年
|
|
Progression Free Survival (PFS) Rate at 6 months by RECIST
時間枠：6 months
|
PFS rate is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 6 months.
Per RECIST 1.1 criteria, Complete Response (CR) = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.
Estimation based on the Kaplan-Meier curve.
|
6 months
|
|
Progression Free Survival (PFS) Rate at 6 months by irRECIST
時間枠：6 months
|
PFS rate is defined as the percentage of patients with disease progression (irPD or relapse from irCR as assessed using irRECIST criteria) or death due to any cause at 6 months.
Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =>30% decrease in tumor burden, irPD is >20% increase in tumor burden compared with nadir, irSD is <30% decrease in tumor burden compared with baseline cannot be established nor <20% increase compared with nadir.
Estimation based on the Kaplan-Meier curve.
|
6 months
|
|
Objective Response Rate (ORR) by RECIST
時間枠：4 years
|
Objective Response Rate (ORR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria.
Per RECIST 1.1 criteria, CR = disappearance of all target lesions and PR is =>30% decrease in sum of diameters of target lesions.
|
4 years
|
|
Objective Response Rate (ORR) by irRECIST
時間枠：4 years
|
Objective Response Rate (irORR) is defined as the percentage of patients achieving a complete response (irCR) or partial response (irPR) based on irRECIST criteria.
Per irRECIST criteria, irCR = disappearance of all lesions and irPR is =>30% decrease in tumor burden.
|
4 years
|
|
Duration of Response by RECIST
時間枠：4 years
|
Number of months from the start date of PR or CR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented.
Per RECIST 1.1 criteria, CR = disappearance of all target lesions, PR is =>30% decrease in sum of diameters of target lesions, and PD is >20% increase in sum of diameters of target lesions.
|
4 years
|
|
Duration of Response by irRECIST
時間枠：4 years
|
Number of months from the start date of irPR or irCR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented.
Per irRECIST criteria, irCR = disappearance of all lesions, irPR is =>30% decrease in tumor burden, and irPD is is >20% increase in tumor burden compared with nadir.
|
4 years
|
|
Disease Control Rate (DCR)
時間枠：4 years
|
DCR is defined as the number of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria at any time during the study.
CR = disappearance of all target lesions, PR is =>30% decrease in sum of diameters of target lesions, PD is >20% increase in sum of diameters of target lesions, SD is <30% decrease or <20% increase in sum of diameters of target lesions.
Estimation based on the Kaplan-Meier curve.
|
4 years
|
|
Progression-Free Survival (PFS)
時間枠：4 years
|
PFS is defined as the number of patients with disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause.
Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions.
Estimation based on the Kaplan-Meier curve.
|
4 years
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Stéphanie Gaillard, MD、Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2016年1月8日
一次修了 (実際)
2020年3月5日
研究の完了 (実際)
2020年3月5日
試験登録日
最初に提出
2015年6月26日
QC基準を満たした最初の提出物
2015年6月29日
最初の投稿 (見積もり)
2015年6月30日
学習記録の更新
投稿された最後の更新 (実際)
2021年4月12日
QC基準を満たした最後の更新が送信されました
2021年4月9日
最終確認日
2021年4月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
原発性腹膜癌の臨床試験
-
Cairo Universityまだ募集していません
-
Taichung Veterans General Hospital完了心毒性 | 非小細胞肺癌（MeSH用語：Carcinoma, Non-Small-Cell Lung） | 薬物関連の副作用および有害反応（MeSH用語） | EGFRチロシンキナーゼ阻害剤台湾
-
Fondazione del Piemonte per l'Oncologia募集乳がん | 卵巣がん | 結腸直腸がん | 黒色腫 (皮膚がん) | 非小細胞肺癌（MeSH用語：Carcinoma, Non-Small-Cell Lung）イタリア
トレメリムマブの臨床試験
-
Riboscience, LLC.募集
-
Chang Gung Memorial Hospitalまだ募集していませんHCC | 免疫療法 | Tace
-
Yoon Jun KimAstraZeneca募集
-
Canadian Cancer Trials GroupAstraZeneca; National Cancer Institute, Naples募集